Osteoprotegerin as a potential therapy for osteoporosis

Current Rheumatology Reports

Volumn 8, Issue 1, 2006, Pages 50-54

  Hamdy, Neveen A T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 162; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

BONE REMODELING; CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; METABOLIC BONE DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

EID: 33750513412     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0026-2     Document Type: Review

References (50)

1. Suda T, Takahashi N, Udagawa N, et al.: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
2. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
3. Duong LT, Rodan GA: Regulation of osteoclast formation and function. Rev Endocr Metab Disord 2001, 2:95-104.
4. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
5. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
6. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003, 423337-4233342. Very clear review article providing insight into the mechanisms of osteoclastogenesis and activation of bone resorption with particular reference to the role of the RANK signalling pathway.
7. Baron R: Arming the osteoclasts. Nat Med 2004, 10:458-460.
8. Tanaka S, Takahashi N, Udagawa N, et al.: Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91:257-263.
9. Lacey DL, Timms E, Tan H-L, et al.: Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
10. Hsu H, Lacey DL, Dunstan CR, et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
11. Kong YY, Yoshida H, Sarosi I, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
12. Sheperd R, Gao Y, Qien W, et al.: IL-7 induces bone loss in estrogen deficient mice by a mechanism involving activation and expansion of TNF producing T lymphocytes. J Bone Miner Res 2003, 18(Suppl 2):S16.
13. Toraldo G, Roggia C, Qian WP, et al.: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003, 100:125-130.
14. Weitzmann MN, Roggia C, Toraldo G, et al.: Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002, 110:1643-1650.
15. Simonet WS, Lacey DL, Dunstan CR, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
16. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
17. Emery JG, McDonnell P, Burke MB, et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367.
18. Wiley SR, Schooley K, Smolak PJ, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
19. Bucay N, Sarosi I, Dunstan CR, et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
20. Li J, Sarosi I, Yan XQ, Morony S, et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000, 97:1566-1571.
21. Mundy GR: The bone microenvironment and metastasis. Cancer Treat Rev 2005, 31(Suppl 1):S11.
22. Dougau W, Tometsko M, Armstrong A, et al.: RANK ligand directly induces osteoclastogenic, angiogenic, chemoattractive and invasive factors on RANK-expressing human cancer cells MDA-MB-231 and PC3. Cancer Treat Rev 2005, 31(Suppl 1):S24.
23. Croucher P, Holen I, Eaton C: Nonosseous effects of osteoprotegerin. Cancer Treat Rev 2005, 31 (Suppl 1):S14. The effect of a single dose of osteoprotegerin in postmenopausal women.
24. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495. Comprehensive review of role of alterations in the RANKL/OPG system in the pathogenesis of a number of diseases affecting the skeleton with an interesting discussion on potential therapeutic implications of these findings.
25. Hofbauer LC, Gori F, Riggs BL, et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
26. Sasaki N, Kusano E, Ando Y, et al.: Glucocorticoid decreases circulating osteoprotegerin (OPG). Nephrol Dial Transplant 2001, 16:479-482.
27. Sivagurunathan S, Muir MM, Brennan TC, et al.: Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005, 20:390-398.
28. Hofbauer LC, Khosla S, Dunstan CR, et al.: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
29. Shevde NK, Bendixen A, Dienger KM, Pike JW: Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000, 977:829-834.
30. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al.: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
31. Pacifia R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996, 11:1043-1051.
32. Riggs BL, Sundeep K, Meltn LJ III: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
33. Bord S, Ireland DC, Beavan SR, Compston JE: The effects of estrogen on osteoprotegerin, RANKL and estrogen receptor expression in human osteoblasts. Bone 2003, 32:136-141.
34. Viereck V, Grundker C, Blaschke S, et al.: Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003, 88:4206-4213.
35. Schett G, Stefan K, Redlich K, et al.: Soluble RANKL and risk of nontraumatic fracture. JAMA 2004, 291:1108-1113.
36. Mezquita-Raya P, de la Higuera M, Fernandez Garcia F, et al.: The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteopor Int 2005, Online.
37. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 4:496-551.
38. Cheng X, Kinosaki M, Takami M, et al.: Disabling of receptor activator of nuclear factor-kB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem 2004, 279:8269-8277.
39. Honore P, Luger NM, Sabino MA, et al.: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganisation of the spinal cord. Nat Med 2000, 6:521-528.
40. Min H, Morony S, Sarosi I, et al.: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474.
41. Bekker PJ, Holloway D, Nakanishi A, et al.: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360. Only study published on the clinical use of osteoprotegerin in postmenopausal women.
42. Body JJ, Greipp P, Coleman RE, et al.: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97(Suppl 3):887-892. Demonstrates that osteoprotegerin is at least as potent as pamidronate in inhibiting cancer-induced bone resorption.
43. Oyajobi BO, Anderson DM, Traianedes K, et al.: Therapeutic efficacy of a soluble receptor activator of nuclear factor kB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001, 61:2572-2578.
44. Bekker PJ, Holloway D, Rasmussen AS, et al.: A single-dose placebo-controlled study of AMG 162, fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066. This paper outlines the antiresorptive efficacy and safety of a single subcutaneous dose of AMG 162 in 49 postmenopausal women in a randomized, double-blind, placebo-controlled, dose escalation study with a follow-up period of 6-9 months.
45. Pan B, Farrugia AN, To LB, et al.: The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004, 19:147-54.
46. Kobayashi Y, Hashimoto F, Miyamoto H, et al.: Force-induced osteoclast apoptpsis in vivo is accompanied by elevation in transforming growth factor b and osteoprotegerin expression. J Bone Miner Res 2000, 15:1924-1934.
47. Onyia JE, Galvin RJ, Ma YL, et al.: Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 2004, 309:369-379.
48. Kostenuik PJ, Paul C, Smith S, et al.: The RANKL antagonist OPG-Fc causes significant increases in cortical bone mineral area, content and density in adult cynomolgus monkeys. J Bone Miner Res 2004, 19(Suppl 1): S19.
49. Smith BB, Cosenza ME, Mancini A, et al.: A toxicity profile of osteoprotegerin in the cynomolgus monkey. Int J Toxicol 2003, 22:403-412.
50. McClung MR, Lewiecki EM, Bolognese MA, et al.: AMG 162 increases bone mineral density (BMD) within 1 month in postmenopausal women with low BMD. J Bone Miner Res. 2004, 19(Suppl 1):S20.